Jones Jennifer L
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States.
Front Psychiatry. 2023 Apr 14;14:1096298. doi: 10.3389/fpsyt.2023.1096298. eCollection 2023.
Alcohol and other substance use disorders are commonly associated with post-traumatic stress disorder (PTSD), and the presence of these comorbidities is associated with worse treatment outcomes. Additionally, disparities in substance and PTSD prevalence have been associated with minority races and ethnicities, and minorities have been shown to be less likely to engage in treatment. Psychedelic-assisted treatments, including 3,4-methylenedioxymethamphetamine (MDMA), have shown preliminary trans-diagnostic effectiveness, however it is unknown how individuals with substance use disorders view the therapeutic potential of MDMA therapy. Previous studies have also shown that minority races and ethnicities are under-represented in the MDMA trials, leading to concerns about inequitable access to clinical treatment.
To explore demographic characteristics related to patient-level perspectives on the therapeutic potential of MDMA-assisted therapy, this study describes data from a nationwide, cross-sectional survey of 918 individuals self-reporting criteria consistent with alcohol or substance use disorders.
Overall, a majority of individuals reported support for medical research of MDMA (68.1%), belief that MDMA-assisted therapy might be a useful treatment (70.1%), and willingness to try MDMA-assisted therapy if it were determined to be an appropriate treatment for them (58.8%). No race or ethnicity differences were found in support for further research or belief in effectiveness, however there were small disparities in terms of willingness to try MDMA-assisted therapy and concerns related to use of this treatment approach.
These results provide insights and future directions as the field of psychedelic-assisted therapy seeks to provide equitable access to clinical care and to diversify research participation.
酒精及其他物质使用障碍通常与创伤后应激障碍（PTSD）相关，这些共病的存在与较差的治疗结果相关。此外，物质使用障碍和PTSD患病率的差异与少数种族和族裔有关，并且已表明少数群体参与治疗的可能性较小。迷幻剂辅助治疗，包括3,4-亚甲基二氧甲基苯丙胺（MDMA），已显示出初步的跨诊断有效性，然而，有物质使用障碍的个体如何看待MDMA治疗的治疗潜力尚不清楚。先前的研究还表明，少数种族和族裔在MDMA试验中的代表性不足，这引发了对临床治疗获取不平等的担忧。
为了探索与患者层面关于MDMA辅助治疗的治疗潜力的观点相关的人口统计学特征，本研究描述了一项对918名自我报告符合酒精或物质使用障碍标准的个体进行的全国性横断面调查的数据。
总体而言，大多数个体报告支持MDMA的医学研究（68.1%），相信MDMA辅助治疗可能是一种有用的治疗方法（70.1%），并且如果确定MDMA辅助治疗适合他们，愿意尝试这种治疗方法（58.8%）。在支持进一步研究或相信有效性方面未发现种族或族裔差异，然而在尝试MDMA辅助治疗的意愿以及对这种治疗方法使用的担忧方面存在微小差异。
随着迷幻剂辅助治疗领域寻求提供平等的临床护理机会并使研究参与多样化，这些结果提供了见解和未来方向。
